Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K
Internal Receptors01:31

Internal Receptors

68.3K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
68.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial intelligence and radiomics on computed tomography for differentiating hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a multimodal integration approach.

BMC medical imaging·2026
Same author

Cancer Cell-Intrinsic Cholesterol Induces Lipid-Associated Macrophage Differentiation via SP1 Palmitoylation to Promote Prostate Cancer Progression.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Edge-aware adaptive hyperspectral acquisition via synergistic dual-camera architecture.

Optics express·2025
Same author

The role of phosphatidylinositol (18:1_18:1) in benign prostatic hyperplasia: an integrated study of Mendelian randomization and network pharmacology.

World journal of urology·2025
Same author

Automated Literature Screening for Hepatocellular Carcinoma Treatment Through Integration of 3 Large Language Models: Methodological Study.

JMIR medical informatics·2025
Same author

Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis.

Journal of cancer research and clinical oncology·2025

Related Experiment Video

Updated: May 10, 2025

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.3K

An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy

Ruilin Zhuang1,2, Ruihui Xie1,2,3, Shirong Peng1,2

  • 1Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.

Journal of Translational Medicine
|April 27, 2025
PubMed
Summary

A new gene signature predicts prostate cancer (PCa) progression and treatment response, identifying patients who may benefit from combined therapies. This signature aids in overcoming anti-androgen resistance for improved PCa outcomes.

Keywords:
Anti-androgen resistanceEnzalutamideFerroptosisImmune checkpointsPLK1 inhibitionPrognostic gene signature

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.5K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K

Related Experiment Videos

Last Updated: May 10, 2025

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.5K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Anti-androgen resistance is a significant clinical hurdle in prostate cancer (PCa) treatment.
  • Lack of a reliable prognostic model hinders personalized therapeutic strategies for PCa patients.

Purpose of the Study:

  • To develop a novel gene signature for predicting anti-androgen resistance in PCa.
  • To evaluate the prognostic and therapeutic implications of this gene signature.

Main Methods:

  • Transcriptomic analysis identified anti-androgen resistance-related differentially expressed genes (ARRDEGs).
  • A prognostic signature was constructed using Cox regression and validated in The Cancer Genome Atlas (TCGA) cohorts.
  • Immune infiltration, immune checkpoint expression, and drug sensitivity were assessed in relation to the signature.

Main Results:

  • A three-gene signature (LMNB1, SSPO, PLK1) stratified PCa patients into high- and low-risk groups.
  • High-risk patients showed shorter recurrence-free survival and distinct immune profiles, including elevated immune checkpoints and M2 macrophage infiltration.
  • PLK1 inhibition enhanced enzalutamide efficacy by inducing ferroptosis, suggesting a strategy to overcome resistance.

Conclusions:

  • A novel ARRDEGs-based signature predicts PCa progression and response to chemotherapy and targeted therapy.
  • This signature, integrated with immune and drug sensitivity analyses, supports precision oncology in PCa.
  • PLK1 inhibition shows promise for enhancing enzalutamide efficacy and overcoming resistance.